Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Today, we are moving to a logo with a new look & feel. Even if we were very keen on our « old » one, the time had come to change our identity.
Right from the beginning, the concept to make 360 changes were out of our mind. It was of a high importance to stick to key elements in order to still be identified as Oncodesign. That is why, we focused on an evolutive approach rather than a radical one.
Over the coming months, we will be harmonizing our graphic identity and updating the website and our documents.